Results 1 to 10 of about 30,241 (197)

A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma [PDF]

World Journal of Surgical Oncology
Background National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for patients with > 10% risk of positivity, consider SLNB with 5–10% risk, and foregoing with
J. Michael Guenther, Andrew Ward, Brian J. Martin, Mark Cripe, Rohit Sharma, Stanley P. Leong, Joseph I. Clark, John Hamner, Timothy Beard   +8 more
doaj   +7 more sources

The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms CP-GEP at identifying patients who can safely forego sentinel lymph node biopsy

SKIN The Journal of Cutaneous Medicine, 2022
Introduction: National guidelines for cutaneous melanoma suggest avoiding sentinel lymph node biopsy (SLNB) if the risk of SLN positivity is <5% (T1a with no high-risk features), considering SLNB if the risk is 5-10% (T1a with additional high-risk features (T1aHR) and T1b), and offering SLNB if the risk is >10% (T2-T4). Because most patients (88%)
Abel Jarell, Brian Martin, Peter Prieto
semanticscholar   +11 more sources

The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients [PDF]

Anticancer Research, 2023
Sentinel lymph node biopsy (SLNB) for patients with cutaneous melanoma is primarily a prognostic procedure that broadly identifies patients who may have disease progression and may warrant additional intervention. However, 88% of patients undergoing SLNB receive a negative result and of those, some will succumb to their disease. One clinical utility of
Michael, Tassavor, Brian J, Martin, Alex M, Glazer   +2 more
semanticscholar   +4 more sources

Prediction of Sentinel Node Positivity Risk in Melanoma Patients: When Appropriate Statistical Methodology was Employed an i31-GEP Test Did Not Outperform a Tool that Uses Clinicopathologic Features Only

SKIN The Journal of Cutaneous Medicine, 2023
Not ...
Serigne Lo, Alexander Varey, Richard Scolyer, John Thompson   +3 more
semanticscholar   +4 more sources

The i31-SLNB Identifies Patients with Cutaneous Melanoma Who Have Less than 5% Risk of SLN Positivity while the CP-GEP does not

SKIN The Journal of Cutaneous Medicine
Introduction: Sentinel lymph node biopsy (SLNB) is a prognostic procedure that can help guide surveillance and treatment management plans for patients with cutaneous melanoma. However, up to 88% of SLNBs are negative, suggesting that most patients may not require SLNB.
J. Michael Guenther, Samuel Dierks, John Vetto   +2 more
semanticscholar   +4 more sources

I31. Economic Evaluation of a Brief Education, Self-Management and Upper Limb Exercise Training Programme in People With Rheumatoid Arthritis [PDF]

Rheumatology, 2015
Lindsay M. Bearne, Billingsley Kaambwa, Julie Ratcliffe, Ernest Choy, David L. Scott, Michael V. Hurley and Victoria L. Manning Division of Health and Social Care Research, King’s College London, London, UK, Flinders Health Economics Group, School of Medicine, Flinders University, Adelaide, Australia, Institute of Infection & Immunity, Cardiff ...
Lindsay Bearne, Billingsley Kaambwa, Julie Ratcliffe, Ernest Choy, David L. Scott, Michael Hurley, Victoria Manning   +6 more
semanticscholar   +3 more sources

Classification of j-maximal spacelike affine translation surfaces in the Minkovski space i31 with density

Tạp chí Khoa học, 2019
An affine translation surface is a graph of a function   introduced by Liu and Yu in 2013. The article considers the spacelike affine translation surfaces in the Minkowski space  with density  establishing the Lagrange’s equation type for -maximal surface, classifying -maximal spacelike affine translation surfaces.
Tran Le Nam
semanticscholar   +4 more sources

Real-World Evidence Confirms Risk Stratification of the 31-GEP and i31-GEP in Prospectively Tested Patients with Stage I-III Cutaneous Melanoma 

SKIN The Journal of Cutaneous Medicine
Introduction: Current American Joint Committee on Cancer (AJCC 8th edition) guidelines in patients with cutaneous melanoma (CM) separate them into risk categories based on the pathological tumor data of Breslow thickness, ulceration status, and sentinel lymph node status.
David Pariser, Jeffrey Sussman, Brian Martin, Lindsay Ackerman, Craig Kraffert, Abel Jarell   +5 more
semanticscholar   +3 more sources

LB1707 Cost implications of i31-GEP as a stratification tool for sentinel node positivity in cutaneous melanoma [PDF]

Journal of Investigative Dermatology, 2023
E. Ma, M.A. Marchetti, E.K. Bartlett, Y. Hu, J.H. Terhune   +4 more
semanticscholar   +3 more sources

The i31-gene expression profile test for cutaneous melanoma identifies patients with head and neck tumors who could forego sentinel lymph node biopsy

SKIN The Journal of Cutaneous Medicine, 2023
Teo Solelymani, Brian Martin, Michael Tassavor   +2 more
semanticscholar   +4 more sources